
Are We on the Verge of Curing Alzheimer’s?
In the Bubble with Andy Slavitt
Adicannemap - What's Controversy?
Adicannemap is an antibody that attacks amyloid deposits in brain. FDA and Medicare had to make a decision on whether the drug should be approved. Adjelm has caused some controversy, but it's not clear if there are any problems with its safety or effectiveness.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.